Tuesday, October 3, 2023
Tuesday, October 3, 2023

Contact: 561.316.3330

Richard John Daly Appointed President of CARsgen Therapeutics Corporation

Richard John Daly (“Mr. Daly”) has been appointed President of CARsgen Therapeutics Corporation, a subsidiary of the Company in the United States.

Richard John Daly will report to Dr. Zonghai Li, Founder, Chairman of the Board, CEO, CSO of CARsgen Therapeutics Holdings Limited.

Mr. Daly will lead the CARsgen U.S. team for the international business activities of CARsgen outside of China, including clinical development, CMC operation, business development, commercialization, investor relations and public relations. Mr. Daly will also contribute to the overall growth strategies and business planning of CARsgen, helping the Company to develop more innovative cell therapies to cancer patients worldwide and make cancer curable.

Mr. Daly brings approximately 30 years of experience in pharmaceutical industry, including leadership positions in multi-national corporations and biotech companies. Prior to joining CARsgen, Mr. Daly served as Chief Operating Officer of Beyond Spring, Inc. (NASDAQ: BYSI). From February 2016 to July 2018, Mr. Daly served as Chief Executive Officer, President and Chairman of Neuralstem, Inc. (NASDAQ: PALI). Mr. Daly served in AstraZeneca as the President of the U.S. Diabetes subsidiary (formerly BMS-AZ Diabetes Alliance). From 1998 to 2011, Mr. Daly served at Takeda and TAP Pharmaceuticals, a joint venture established between Takeda and Abbott Laboratories, holding several leadership positions, including the Executive Vice President at Takeda Pharmaceutical North America and the Senior Vice President of marketing at TAP Pharmaceuticals. Mr. Daly currently sits on the boards of directors of Catalyst Pharmaceuticals (NASDAQ: CPRX) and Opiant Pharmaceuticals (NASDAQ: OPNT).

Mr. Daly holds an MBA from Kellogg School of Management at Northwestern University and a Bachelor of Science degree from University of Notre Dame.

Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics Holdings Limited, said, “We warmly welcome Mr. Daly to join CARsgen. Mr. Daly is an industry veteran with approximately 30 years of successful experiences in pharmaceutical companies, including leadership positions in multi-national organizations such as Takeda, BMS, and AstraZeneca. The breadth of Mr. Daly’s experiences in sales and marketing, business development, and operation management makes him an ideal fit to lead the team of our U.S. subsidiary. Mr. Daly joins us at an exciting time of the company’s accelerating growth and development, and it resonates with our ambition for the global markets. The joining of Mr. Daly will further accelerate our international business activities, including clinical development, CMC operation, business development, etc. Together with Mr. Daly and the team, we are committed to developing more innovative cell therapies to cancer patients worldwide and make cancer curable.”

Mr. Daly, President of CARsgen Therapeutics Corporation, said, “The unique CARsgen scientific, clinical and manufacturing platform is incredibly exciting and has the potential to deliver improved therapeutic options for cancer patients. I am honored and thrilled to be joining the CARsgen team at this pivotal time and I look forward to working with our talented team to continue to build the platform that can deliver on the CARsgen promise of providing enhanced care for patients and, more importantly, making cancer curable.”

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.


Broken String Biosciences Strengthens Senior Leadership Team

Bringing significant expertise in their respective fields, Vincent Smith, PhD and Jessica Rich appointments are a key part of Broken String’s strategy to deliver on its Series A goals, which include the continued development of its INDUCE-seq™ DNA break-mapping platform and acceleration of its commercial expansion across global markets.

New Chief Sales Officer at Encare with Focus on Continued Global Expansion

The HealthTech company Encare has recruited Lotta Sellén as the new Chief Sales Officer (CSO). Lotta Sellén has solid experience in the pharmaceutical, healthcare and HealthTech industries.

CorWave Appoints Magalie Durrèche as Chief Financial Officer

Magalie Durrèche will oversee the financial management and participate in the strategic planning and fundraising of CorWave, a company developing and manufacturing a blood pump based on breakthrough technology. She succeeds Zina Hamoumi, who served as Chief Financial Officer for five years before deciding to focus on other projects.

Veracyte Names Dr Phillip G Febbo Chief Scientific Officer and Chief Medical Officer

“Phil G Febbo is an exceptional leader with a strong track record of driving successful commercialization of molecular tests through evidence development, guideline inclusion and key opinion leader support,” said Mr. Stapley. “His experience and expertise will be critical to further enhancing our ability to serve our customers and, ultimately, to transforming cancer care for patients all over the world.”

GrayMatters Health Expands US Executive Team, Including Appointment of Dr Aron Tendler as Chief Medical Office

Dr Aaron Tendler is a board-certified psychiatrist based in Palm Beach, Florida, bringing over 20 years of experience as an industry leader researching novel treatments for mental health disorders.

By using this website you agree to accept Medical Device News Magazine Privacy Policy